



OpGen and Merck's ILÚM Health Solutions to Host Event at VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship

March 25, 2019

GAITHERSBURG, Md., March 25, 2019 (GLOBE NEWSWIRE) -- [OpGen, Inc.](#) (Nasdaq: OPGN) announced today it will host an event with ILÚM Health Solutions, LLC ("ILÚM"), a wholly owned subsidiary of Merck's Healthcare Services and Solutions, at the [VIII International Symposium on Hospital Acquired Infections and Antimicrobial Stewardship](#), held March 27-29 at the Intercontinental Hotel in Santiago de Cali, Colombia. Both companies are sponsors of the conference and will have an exhibit.

Event Details:

Title: "Strengthening the Power of Antimicrobial Stewardship through Rapid Diagnostics and Clinical Decision Support Solutions"

Day: Wednesday, March 27

Time: 9:00am-12:00pm (Colombia Standard Time)

Location: Salón Río Lilis on the 2nd floor of the Intercontinental Hotel

"We look forward to returning to Colombia to discuss the urgent global issue of antimicrobial stewardship with the leading health and medical minds from Latin America," said Evan Jones, Chairman and Chief Executive Officer of OpGen. "As the threat from antibiotic-resistant bacteria and hospital acquired infections continues to grow worldwide, it remains crucial for healthcare organizations to identify innovative solutions, like those from OpGen and ILÚM, to fight, prevent, and contain the spread of multidrug-resistant pathogens."

Both companies will showcase their products to key opinion leaders from major healthcare institutions in Colombia as well as other Latin American countries, such as Argentina, Brazil, Chile, Guatemala, Mexico and Peru. OpGen will present its *QuickFISH*®, *Acuitas*® AMR Gene Panel, and *Acuitas Lighthouse*® solutions. ILÚM will present *Insight*, a smartphone-based clinical decision support solution for antimicrobial stewardship and infection control that was developed under [a Centers for Disease Control and Prevention \(CDC\) contract](#) and in partnership with OpGen and Universidad El Bosque of Bogota, Colombia.

About ILÚM

ILÚM Health Solutions is a provider of technology and services to support precision medicine for infectious disease management, clinical decision-support and precision antibiotic therapy. ILÚM is part of [Healthcare Services & Solutions](#), LLC, a wholly-owned subsidiary of Merck & Co., Inc. Its *Insight* solution and other portfolio products are commercially available and in use in major health systems. For more information, visit www.ILUMhealthsolutions.com.

About OpGen

OpGen, Inc. is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. We are developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs.

Our molecular diagnostics and informatics products, product candidates and services combine our *Acuitas* molecular diagnostics and *Acuitas Lighthouse* informatics platform for use with our proprietary, curated MDRO knowledgebase. We are working to deliver our products and services, some in development, to a global network of customers and partners. The *Acuitas* AMR Gene Panel (RUO) is intended for Research Use Only and is not for use in diagnostic procedures. The *Acuitas Lighthouse* Software is not distributed commercially for antibiotic resistance prediction and is not for use in diagnostic procedures. For more information, please visit www.opgen.com.

OpGen, *Acuitas*, and *Acuitas Lighthouse* are registered trademarks of OpGen, Inc.

OpGen Contact:

Michael Farmer
Vice President, Marketing
(240) 813-1284
mfarmer@opgen.com
InvestorRelations@opgen.com

Press Contact:

Matthew Bretzius
[FischTank Marketing and PR](#)
matt@fishtankpr.com

Investor Contacts:

Joe Green
Edison Group
jgreen@edisongroup.com



Source: OpGen, Inc.